Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

5.85$0.09 1.56%
At close       04:00 PM   

Stock Snapshot

5.76
Prev. Close
5.79
Open
384.29M
Market Cap
2.10M
Number of Shares
5.66
Day Low
5.86
Day High
5.85
-
P/E Ratio
53.68M
Free Float in %
-0.85
EPS 2021
0.75
Book Value per Share
-
Cash Flow per Share
Pieris Pharmaceuticals, Inc. (PIRS)
Pieris Pharmaceuticals, Inc. (PIRS) stock rallied over 1.56% intraday to trade at $5.85 share on NASDAQ. The stock opened with a gain of % at $5.79 and touched an intraday high of $5.86, rising 1.74% against the last close of $5.76. The stock went to a low of $5.66 during the session.

Historical Data

DateOpenCloseDaily HighDaily LowVolume
2021-09-10$5.88$5.71$5.89$5.501,394,779
2021-09-03$5.33$5.29$5.39$4.83193,500,000
2021-09-02$5.42$5.36$5.48$5.18188,230,000
2021-09-01$5.37$5.41$5.64$5.25206,100,000
2021-08-31$5.00$5.39$5.44$4.96298,860,000
2021-08-30$4.66$4.99$5.36$4.63677,300,000
2021-08-27$4.47$4.59$4.65$4.43116,060,000
2021-08-26$4.30$4.46$4.53$4.29106,810,000
2021-08-25$4.17$4.37$4.43$4.02167,320,000
2021-08-24$4.34$4.15$4.34$4.06174,160,000
2021-08-23$4.04$4.32$4.34$4.04134,420,000
Pieris Pharmaceuticals, Inc.
255 State Street
9th Floor
Boston, MA 02109
United States

http://www.pieris.com
857 246 8998
Employees
114
Sector
Healthcare
Sales or Revenue
23.70M
Industry
Biotechnology
5Y Sales Change
58.50
Fiscal Year Ends
2020-12-30

Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company also develops PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc.; and license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a research collaboration with the laboratories of University of Pittsburgh. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam